Leerink Partners analyst, Jason Gerberry, weighed in on the PFE-AGN and recommends buying shares of Allergen (NYSE: AGN) at the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Mergers and Acquisitions

Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations April 6, 2016 7:13 AM Treasury Action More than a Wrinkle for Pfizer (PFE)/Allergan (AGN) Deal - JefferiesApril 5, 2016 7:19 AM New Treasury Action Could Block, or Significantly Change Pfizer (PFE)/Allergan (AGN) Deal - BMO CapitalApril 5, 2016 6:53 AM Allergen (AGN) Trading Below Standalone Value Following New Treasury Action - RBCApril 5, 2016 6:42 AM Allergan (AGN), Pfizer (PFE) Comment on U.S. Treasury Action; Won't Comment on Potential ImpactApril 5, 2016 6:37 AM Pfizer and Allergan Issue StatementApril 4, 2016 7:05 PM Pfizer (PFE) Conducting Review of U.S. Treasury Notice, Won't Speculate on Potential Effect - Bloomberg, Citing SpokeswomanApril 4, 2016 5:53 PM UPDATE: Allergan (AGN) Pressured After U.S. Treasury, IRS Seek to Reduce Benefits of InversionsApril 4, 2016 5:24 PM Allergan (AGN) Slammed on New U.S. Treasury Inversion Action; Pfizer (PFE) HigherApril 4, 2016 5:24 PM